Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Alternative and complementary therapies for inflammatory bowel disease

¹Allgemeines Krankenhaus, and Medical University of Vienna, Vienna, Austria. alfred.gangl@meduniwien.ac.at

Nature Clinical Practice. Gastroenterology & Hepatology

|April 4, 2006

Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011.

Journal of clinical gastroenterology·2012

Same author

Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2011

Same author

Public awareness of Crohn's disease and ulcerative colitis: A national survey.

Journal of Crohn's & colitis·2010

Same author

Long-term outcome in patients with ulcerative colitis treated with intravenous cyclosporine A is determined by previous exposure to thiopurines.

Journal of Crohn's & colitis·2010

Same author

von Willebrand factor antigen: a novel on-treatment predictor of response to antiviral therapy in chronic hepatitis C genotypes 1 and 4.

Antiviral therapy·2010

Same author

Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C virus coinfection treated with ribavirin and highly active antiretroviral therapy.

The Journal of infectious diseases·2010